STOCK TITAN

ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

ImmunityBio (NASDAQ: IBRX) has announced its 2024 Annual Meeting of Stockholders, scheduled for June 11, 2024, at 9:30 a.m. PT. The meeting will be held virtually with no physical location. Shareholders of record as of April 17, 2024, are eligible to vote and participate.

Chief Executive Officer Richard Adcock will provide a business update following the formal business proceedings. Non-shareholders can join the virtual meeting as guests. A replay will be available within 24 hours on the company's investor relations website and remain accessible for 90 days.

Additional presentations and webcasts on company developments can also be found on the investor relations site, which may contain material information.

Positive
  • Announcement of the 2024 Annual Meeting, providing transparency and engagement opportunities for shareholders.
  • Virtual format increases accessibility for all interested parties.
  • Replay availability for 90 days ensures comprehensive access to information.
  • CEO Richard Adcock will provide a business update, suggesting transparency and upcoming developments.
Negative
  • Virtual-only format might limit interaction and engagement compared to in-person meetings.
  • No specific financial or clinical data updates were provided in this announcement.

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX) announced today that its 2024 Annual Meeting of Stockholders will be held on Tuesday, June 11, 2024 at 9:30 a.m. Pacific Time. The Annual Meeting will be held in a virtual-only format and there will not be a physical location for the Annual Meeting. Stockholders of record at the close of business on April 17, 2024 are entitled to vote at and participate in the Annual Meeting.

Richard Adcock, the Company’s Chief Executive Officer and President, will provide a business update after the formal business of the Annual Meeting has ended. All interested parties are welcome to attend the Annual Meeting and listen to the Company update. Non-stockholders can attend the virtual Annual Meeting by using the following link: virtualshareholdermeeting.com/IBRX2024 and clicking on the “GUEST” button to join the meeting. This website will available 15 minutes prior to the start of the Annual Meeting.

A playback of this event will be available for replay within 24 hours after the completion of the Annual Meeting at ir.immunitybio.com/ for at least 90 days after the event.

Availability of Other Information about ImmunityBio, Inc.

A playback of this event, along with other selected webcasts and presentations regarding developments in the Company’s business given by management at certain investor and medical conferences, can be found on the Company’s Investor Relations website, ir.immunitybio.com, under “CompanyꟷEvents & Presentations.” The information posted on this website could be deemed to be material information. As a result, investors, the media, and others interested in ImmunityBio are encouraged to review this information on a regular basis. The contents of the Company’s websites, or any other website that may be accessed from the Company’s website, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

About ImmunityBio

ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The company’s range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA® is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer that activates natural killer cells, T cells, and memory T cells for a long duration response. The company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.

For more information, please visit: www.immunitybio.com

Forward-Looking Statements

This press release and the event referenced herein may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding anticipated event timing and content, data and results from clinical trials and potential implications therefrom, commercialization plans and timelines, including product availability and shipments, potential regulatory pathways and approval requests and submissions, FDA meetings, timelines and potential results therefrom, the regulatory review process and timing thereof, market and prevalence data, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, information regarding ongoing pre-clinical studies and clinical trials, potential future uses and applications of ANKTIVA and use in cancer vaccines and across multiple tumor types, ImmunityBio’s financial condition, and ImmunityBio’s approved product and investigational agents as compared to existing treatment options, among others. Statements in this presentation that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “goal,” “could,” “estimates,” “scheduled,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “indicate,” “projects,” “seeks,” “should,” “will,” “strategy,” and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio’s management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio’s statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) the risks and uncertainties associated with commercial launch execution, success and timing, (ii) risks and uncertainties related to the regulatory submission and review process, (iii) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (iv) potential delays in product availability and regulatory approvals, (v) risks and uncertainties associated with third party collaborations and agreements, (vi) whether the BCG manufactured by Serum Institute of India will receive regulatory approval in the U.S. and/or other regions, (vii) ImmunityBio’s ability to retain and hire key personnel, (viii) ImmunityBio’s ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (ix) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (x) ImmunityBio’s ability to successfully commercialize its approved product and product candidates and uncertainties around regulatory reviews and approvals, (xi) ImmunityBio’s ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xii) ImmunityBio’s ability to obtain, maintain, protect and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio’s business are described under the heading “Risk Factors” in the Company’s Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on March 19, 2024 and the Company’s Form 10-Q filed with the SEC on May 9, 2024, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC’s website at www.sec.gov. ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.

Investors

Hemanth Ramaprakash, PhD, MBA

ImmunityBio, Inc.

+1 858-746-9289

Hemanth.Ramaprakash@ImmunityBio.com

Media

Greg Tenor

Salutem

+1 717-919-6794

Gregory.Tenor@Salutemcomms.com

Source: ImmunityBio, Inc.

FAQ

When is ImmunityBio's 2024 Annual Meeting of Stockholders?

ImmunityBio's 2024 Annual Meeting is scheduled for June 11, 2024, at 9:30 a.m. PT.

How can shareholders participate in ImmunityBio's 2024 Annual Meeting?

Shareholders of record as of April 17, 2024, can participate in the virtual-only Annual Meeting.

Can non-shareholders attend the ImmunityBio 2024 Annual Meeting?

Yes, non-shareholders can attend by accessing the meeting through the provided link as guests.

Will there be a business update during the ImmunityBio 2024 Annual Meeting?

Yes, CEO Richard Adcock will provide a business update following the formal business proceedings.

Where can I access the replay of ImmunityBio's 2024 Annual Meeting?

The replay will be available on ImmunityBio's investor relations website within 24 hours after the meeting and remain accessible for 90 days.

ImmunityBio, Inc.

NASDAQ:IBRX

IBRX Rankings

IBRX Latest News

IBRX Stock Data

4.58B
691.57M
77.59%
9.83%
7.73%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO